The drug celecoxib may be a safer alternative for treating preterm labor than traditional therapies, according to a preliminary study led by Washington University School of Medicine in St. Louis.
The study is published at the end of the month in the September issue of the American Journal of Obstetrics and Gynecology, and appears on the journal’s website. One of the established treatments to prevent preterm delivery is indomethacin, a drug used to slow uterine contractions and delay delivery.
But indomethacin is associated with severe side effects. Recent research suggests that celecoxib, also known as celebrex, may be a safer alternative. This study is the first clinical trial testing celecoxib in pregnant women. “Celecoxib appears to be safer, particularly for the fetus,” says Yoel Sadovsky, M.D., director of the Division of Genetics, Maternal-Fetal Medicine and Ultrasound at the School of Medicine.
“These preliminary results also suggest that celecoxib is just as effective, and we are currently planning a larger trial to further examine its effectiveness.”
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!